The Bundestag adopted a comprehensive austerity package to finance the healthcare system on July 10. But the SHI Stabilization Act (GKV-BStabG) only resolves the structural problems of the statutory health insurance (SHI) system on a temporary basis. And it sends the wrong signals at the wrong time to Germany as a location for innovation.
Federal Health Minister Nina Warken has, in a short period of time, closed funding gaps that opened up during previous legislative terms. She has initiated and pushed through a genuine financing reform for the statutory health insurance system. The SHI Contribution Rate Stabilization Act (GKV-BStabG), adopted on July 10, 2026, with 319 votes in the Bundestag and approved by the Bundesrat on the same day, is the first major reform initiative of the CDU, CSU, and SPD coalition. Politically, it is without question a success. That the structural funding gap of approximately €19 billion for 2027 demanded action was never in doubt. The Minister has successfully met that pressure with an enacted law, thereby preventing, from today's perspective, short-term contribution rate increases.
And yet: anyone who analyzes the law soberly quickly encounters three unresolved problems: one of a fiscal nature, one systemic, and one strategic. They deserve public attention, because what comes after the reform is at least as important.
A breathing space, not a solution
The Federal Ministry of Health itself acknowledges what many observers have been saying for weeks: from 2029 onward, the SHI system will once again face a deficit of €3.4 billion, rising to €6 billion by 2030. The law buys the system a breathing space through 2028 at most.
This candor is notable. But it also makes clear that a further reform law must follow within the current legislative term – at the latest after the Finance Commission's final report later this year. At best, there will once again be a substantiated debate about extraneous insurance benefits within the SHI system and their financing through tax revenues. The fact that this burden continues to fall on contributors leads to lasting frustration among many stakeholders across the German healthcare system.
Who pays the bill
In the parliamentary process, the distribution of burdens under the law shifted once more: hospitals, physicians, and insured individuals are less burdened than under the cabinet draft. For the pharmaceutical industry, the burdens were further increased – and on three fronts simultaneously.
The total manufacturer rebate rises to 15.5% through the new fixed additional rebate of 8.5%. This alone increases the industry's financing contribution in 2027 – based on calculations by the German industry association vfa – from originally expected €1.1 billion to approximately €3.2 billion.
The rebate factor in the price-volume mechanism was tightened by 50%.
A higher vaccine rebate of 9% combined with a price moratorium through the end of 2030 hits manufacturers of patent-protected vaccines with a double burden. In total, the additional burdens amount to approximately €4.5 billion through 2030.
The fact that the outcome is not a dynamic manufacturer rebate, but rather a fixed rebate that offers the industry planning certainty, is logical and right. Voices in favor of the dynamic manufacturer rebate were even heard from within the Federal Joint Committee (G-BA). But no one had envisaged this extreme level.
The open flank: Pressure on Germany as an investment location
Even the previous coalition government had identified the pharmaceutical industry as a key sector. The current government acknowledges the sector's innovation potential. Rightly so, because Germany – with its research-based pharmaceutical industry, its highly qualified jobs, and its global research excellence – holds a locational advantage that cannot be replicated at the touch of a button. International pressure is currently creating incentives for relocation rather than settlement.
But this advantage is not a law of nature. The pharma and medical technology dialogue is expected to deliver concrete recommendations by the second half of 2026, from which a national pharma and MedTech strategy is to emerge. This is the right framework, but expectations must remain realistic. The most consequential decisions of recent weeks were not taken in the working groups of the dialogue, but in the mediation process surrounding the GKV-BStabG.
And yet there are now concrete measures on the table that could help restore confidence in Germany as a location for innovation and research:
A modern AMNOG 2.0. The existing benefit assessment procedure was an innovative step at the time. In a world of personalized medicine and data-driven therapies, it has reached its limits. For medicines with small patient populations, limited budget impact, or novel mechanisms of action, adapted evidence requirements and faster procedures are needed. Those developing a therapy for a rare disease today also need clarity on access to the German market.
Location incentives beyond the SHI. The exemption provision in the new law – the exemption from the additional rebate for active substances where at least 5% of clinical trial participants were enrolled at trial sites in Germany – is a start, but a limited one. A broader location exemption clause, which would give companies with demonstrable value creation and jobs in Germany a better position on the manufacturer rebate - the so-called "Germany discount" - was discussed in the parliamentary process but ultimately not incorporated into the law. Coalition sources cited European state aid law constraints as the reason; the issue has been referred to the ongoing pharma dialogue. But it must now land there in binding terms – together with further instruments outside the SHI system: funding through the Federal Ministry for Economic Affairs (BMWE), EU instruments, and tax incentives for clinical development. The advantage of such measures is clear: they strengthen Germany as a research location without placing additional strain on an already stretched solidarity system.
Geopolitics does not wait
The geopolitical dimension of this debate is not a footnote. On June 18, 2026, U.S. Trade Representative Jamieson Greer formally initiated a Section 301 investigation against Germany, arguing that German reimbursement practices systematically disadvantage U.S. pharmaceutical companies and effectively force U.S. patients to cross-subsidize global R&D. The USTR explicitly took into account the further development of the GKV-BStabG and specifically identified the manufacturer rebate under § 130a SGB V as well as confidential rebate agreements as concrete mechanisms.
The investigation does not impose immediate tariffs. It opens a structured process with a comment period until August 10 and a hearing on September 22, 2026. But it connects the domestic legislative debate directly with the bilateral trade track for the first time. And it does so at a moment when the pharmaceutical industry is already carrying 15% Section 232 tariffs that have been in force since July 2026. A cumulative additional burden would be substantial.
At the same time, pressure is growing from another direction. China has declared biotechnology a strategically key industry and is investing massively: state funding, attractive conditions for returning scientists, favorable approval practices. Chinese biotech companies closed deals worth approximately $7.3 billion at the JPMorgan Healthcare Conference in early 2026 – more than all other countries combined. Researchers have put the implication plainly: until now, knowledge was produced in Germany and Europe, with China as the sales market. This dynamic could reverse in the future.
What matters now
A stabilization of contribution rates was necessary, and has been achieved. The decisive question is what the second half of 2026 will bring politically.
Three developments will show whether Germany takes its role as a location for innovation seriously.
Whether the pharma dialogue moves beyond process logic and translates through the pharma strategy into concrete outcomes for the AMNOG procedure. Outcomes that deliver good conditions for clinical research and planning certainty for market launches.
How the federal government handles the Section 301 investigation. The structured process that Washington has opened leaves room for a differentiated positioning – bilaterally, but also through the European Commission, which has sole competence in trade matters. This opportunity should be used.
Whether the next SHI reform, which will follow the Finance Commission's final report, takes a structurally broader approach than the GKV-BStabG – including on the question of who pays for extraneous insurance benefits.
Germany is one of the few countries where pharmaceutical innovation is still genuinely at home: in research, in production, in clinical development. For this to remain the case in the future, the right framework conditions are needed – and a clear commitment to medical innovation as a decisive growth area for Germany, including from an economic perspective. Policy for Germany as a pharmaceutical location must therefore be understood as economic policy, and no longer as an appendage or even a burden on the healthcare system.
